Preferred Label : Exagamglogene Autotemcel;

NCIt synonyms : Autologous CRISPR-Cas9 Genetically-modified CD34 HSPCs CTX001; Autologous CD34-positive BCL11A Enhancer-disrupted HSPCs CTX001; Autologous CD34 HSPCs Modified with CRISPR-Cas9 at the Erythroid Lineage-specific Enhancer of the BCL11A Gene; Autologous CRISPR-Cas9 Engineered CD34 hHSPCs CTX001; Autologous CRISPR-Cas9 Modified/ BCL11A Enhancer-disrupted CD34-positive HSPCs CTX001; Autologous CRISPR-Cas9 Modified/BCL11A Enhancer-disrupted CD34-positive Human Hematopoietic Stem and Progenitor Cells CTX001;

NCIt definition : A population of autologous cluster of differentiation 34 (CD34)-positive human hematopoietic stem and progenitor cells (hHSPCs) that are ex-vivo gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex at the erythroid lineage-specific enhancer of the B-cell lymphoma/leukemia 11A (BCL11A) gene, with potential usage for transplantation in patients with sickle cell disease (SCD) and beta-thalassemia. CD34-positive HSPCs are isolated from human blood upon apheresis and are genetically modified in vitro using CRISPR/Cas9 technology to specifically disrupt the erythroid enhancer of the BCL11A gene. As BCL11A is a suppressor of fetal hemoglobin (HbF; hemoglobin F) expression, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from CTX001. Upon infusion back into the patient following myeloablative, conditioning chemotherapy, exagamglogene autotemcel can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. The increased production of high levels of HbF in red blood cells (RBCs) compensates for the defective or reduced adult hemoglobin (Hb) in patients with SCD and beta-thalassemia. HbF is a form of the oxygen carrying Hb that is naturally present at birth and is then replaced by the adult form of hemoglobin.;

UNII : S53L777GM8;

Molecule name : CTX 001; CTX-001;

NCI Metathesaurus CUI : CL1378853;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/casgevy
2025
false
false
false
France
French
biological products
exagamglogene autotemcel
Exagamglogene Autotemcel
risk management
beta-Thalassemia
Transfusion Dependent Beta Thalassemia
adolescent
adult
Cell positive for CD34 antigen (cell)
infusions, intravenous
young adult
anemia, sickle cell
drug information

---
https://ansm.sante.fr/actualites/avis-de-lansm-du-19-12-2023-sur-le-medicament-casgevy-le-cadre-dune-demande-daap
2024
false
false
false
France
French
drug information
exagamglogene autotemcel
Exagamglogene Autotemcel
Transfusion Dependent Beta Thalassemia

---
https://www.has-sante.fr/jcms/p_3545557/fr/casgevy-exagamglogene-autotemcel-ss-thalassemie-dependante-des-transfusions-tdt
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Exagamglogene Autotemcel
exagamglogene autotemcel
gene therapy
Transfusion Dependent Beta Thalassemia
beta-Thalassemia
adolescent
young adult
infusions, intravenous
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3534430/fr/casgevy-exagamglogene-autotemcel-drepanocytose-severe
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
exagamglogene autotemcel
young adult
adolescent
adult
blood transfusion
evaluation of the transparency committee
Exagamglogene Autotemcel
anemia, sickle cell

---
https://www.has-sante.fr/jcms/p_3541918/fr/casgevy-exagamglogene-autotemcel-drepanocytose-severe-chez-les-patients-ages-de-plus-de-12-ans
2024
false
false
false
France
adolescent
adult
insurance, health, reimbursement
treatment outcome
exagamglogene autotemcel
infusions, intravenous
cell therapy
Genetically Engineered Hematopoietic Stem Progenitor Cells
Exagamglogene Autotemcel
evaluation of the transparency committee
anemia, sickle cell

---
https://www.has-sante.fr/jcms/p_3490695/fr/casgevy-exagamglogene-autotemcel-thalassemie-dependante-des-transfusions-tdt
2024
false
false
false
France
biological products
insurance, health, reimbursement
treatment outcome
Transfusion Dependent Beta Thalassemia
beta-Thalassemia
exagamglogene autotemcel
adolescent
young adult
infusions, intravenous
adoptive transfer
evaluation of the transparency committee
Exagamglogene Autotemcel

---
https://www.ema.europa.eu/en/medicines/human/EPAR/casgevy
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Exagamglogene Autotemcel
Exagamglogene Autotemcel
exagamglogene autotemcel
beta-Thalassemia
Transfusion Dependent Beta Thalassemia
anemia, sickle cell
adolescent
adult
orphan drug production
infusions, intravenous
hematopoietic stem cell transplantation
transplantation conditioning
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
cell therapy

---
Nous contacter.
14/07/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.